TW200927161A - Composition containing granulocyte colony stimulating factor (GCSF) for hair growth - Google Patents

Abstract

The present technology relates to the use of Granulocyte Colony Stimulating Factor (GCSF) alone or in combination with one or more of Vascular Endothelial Growth Factor (VEGF) or Epidermal Growth Factor (EGF) in a pharmaceutical composition to inhibit alopecia and to promote hair growth. Uses of GCSF in the treatment of alopecia and in the production of a medicament for the treatment of alopecia are also provided. The technology can he used in human, veterinary and experimental medicine, more specifically in cosmetics and dermatology.

Description

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to the use of a granulocyte colony stimulating factor alone or in combination with other growth factors for the treatment of alopecia. [Prior Art] BACKGROUND OF THE INVENTION During normal hair growth, hair follicles undergo a rapid transition from a resting phase [telogen] to a follicular keratinocyte (proliferation) and the elongation of the hair shaft and the transformation of the growth phase [anagenation] of the thickening. The anagen phase, in turn, causes the regression phase of the follicle (resting phase) to undergo a regression phase [catagen], which lasts until a new hair shaft is in the subsequent growth phase. It is generated during the current stored hair follicles. These cyclic changes involve rapid remodeling of the epithelium of the hair follicle and the epithelial and dermal components. In some people, the normal period is disturbed and hair loss occurs. This is meant to be alopecia °. It has been shown that basic fibroblast growth factor (bFGF) affects hair follicle growth in mice during different hair cycle stages. Vascular Endothelial Growth Factor (Vascular 200927161)

Endothelial Growth Factor (VEGF) has also been shown to stimulate hair growth via neovascularization. In addition, certain well-known anti-alopecia agents [such as minocyclines] have been proposed to act via the induction of growth factors (Lachgar et al. 1998). Another growth factor that has been suggested to play an important role in combating hair loss is Epidermal Growth Factor (EGF). Another growth factor is the Granul〇cyte Colony Stimulating Factor (GCSF). It belongs to the group that regulates the differentiation of stem cells and the proliferation of community stimulating factors. SUMMARY OF THE INVENTION The present technology results in accelerated hair re-growth and increased hair follicle size [which causes hair thickening]. Hair growth can be promoted using GCSF, VEGF, and EGF alone or in a combination thereof. Furthermore, inhibition of GCSF, VEGF, and EGF reduces hair growth and hair thickening. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 shows the amino acid sequence of GCSF according to a specific example of the present technology. Figure 2 shows the amino acid sequence of VEGF according to a specific example of the present technology. [Embodiment] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The present technology is directed to use in an individual having an insufficient amount of hair or an insufficient hair growth rate of 200927161. The individual may suffer from genetic pattern baldness [hormonal disorder that reduces hair growth], is or has been treated to inhibit hair growth [eg, radiation, chemotherapy (chemotherapy) Or a drug that inhibits hair growth] or a surgical procedure that requires hair growth [such as a skin graft]. One or more of the hair's thickness and hair length can be increased. The technology can also be used to maintain hair.实施 Examples Example 1 The purpose of this study was to investigate the effect of growth factor GCSF on the growth of mouse hair. Materials and Methods GCSF was purchased from R&D System, USA (via; Donggan, 50 pg per tube). The test group mice were injected with 50 μί of a saline solution containing 0.1 pg of GCSF (0.002 pg/pL) (〇·9% w gasified sodium in water). The control mice were injected with 50 pL of an aqueous saline solution (0.9% sodium chloride in water). Each group (test group and control group) had 15 mice, of which 5 were tested at one time. The mice were injected subcutaneously with a GCSF solution or a saline solution. Results The results of this study are shown below. The length of the hair was measured using a caliper with a magnifier, and an average of 20 hairs per sample was taken and reported. 200927161 Length of mice treated at 11 days (cm) Length at 17 days (cm) #1 Control group 0.3 0.45 #2 Control group 0.25 0.35 #3 Control group 0.35 0.45 #4 GCSF 0.45 0.65 #5 GCSF 0.4 0.6 #6 GCSF 0.45 0.55 The average hair size (measured according to hair length) in the control group of mice was approximately 0.3 cm on day 11 and approximately 0.4 cm on day 17 〇 in GCSF-treated population The average hair size in the group was 0.45 cm on day 11 and 0.6 cm on day 17. Example 2 Materials and Methods Stock solution G: 0.1 mg/mL GCSF in a saline solution (0.9% sodium hydride in water). Stock solution E: 0.5 mg/mL EGF in Phosphate buffered saline. Mixture A (for Group A): sterile saline (0.9% sodium sulphate in water). Mixture B (for Group B): 36 pg/mL VEGF in saline and 3 pg/mL GCSF. It was prepared by mixing 50 pg of VEGF and 40 μl of stock solution G in 1,260 pL of saline. Mixture C (for Group C): 30 pg/mL EGF in saline and 3 pg/mL GCSF. It was prepared by mixing 80 μL of the stock solution E, 1,180 pL of saline, and 40 μl of the stock solution G. 200927161 Mixture D (for group d): % pg/mL of VEGF in saline, 30 pg/mL EGF with 3 pg/mL·GCSF, and 50 pg VEGF. It was prepared by mixing 80 a stock solution e, a 1,130 μL saline solution, and a 40 μί stock solution G. The test group and the control group mice were injected with one of the mixture A, 、, C or D of 5 。. Hair length is measured in μ days after treatment. Measurement of hair length at day 19 (in mm): Group 1 2 3 4 5 Average (mm) A 9 7 7 8 8 8 B 12 9 10 11 12 11 C 10 9 10 10 11 10 D 11 12 12 10 13 11 The average hair length in the control group (Group A) was 78 mm and in the group treated with GCSF plus VEGF (group) The average hair length in group B) was 10.8 mm. The average hair length in the group treated with GCSF plus EGF (group c) was 1〇. The average hair length in the group treated with EGF plus VEGF (Group D) was u 6 mm ° Example 3 To explore the utility of the growth factor VEGFW & GCSF for mouse hair growth, one study was based on The following were designed: 7 200927161 Compound Group A Group Β Compound V (VEGF) — 1.0 pg/mouse (50 pg/kg) Compound G (GCSF) — 0.10 pg/mouse (5 pg/kg) Mice Number (20 g each) 5 5 Injectable volume 50 μΐ 50 μΐ Weekly injections 3 3 weeks 2 2 Materials and Methods Mice: 10 C57BL/6J, 8 weeks old, male (20 grams each) ). VEGF (165 amino acids): VEGF was used at a final concentration of 50 pg/kg per injection in mice. Therefore each injection contains 1 pg. Each mouse was injected a total of 6 times. GCSF: GCSF was used at a final concentration of 5 pg/kg per injection in mice. Therefore each injection contains 0.1 Kg. Each mouse was injected a total of 6 times. Preparation of VEGF l〇x stock solution (0.2 μβ/μ1): 50 pg of VEGF was dissolved in 0.9% sodium hydride to a final volume of 250 pL. Preparation of GCSF's l〇x stock solution (0.02 μβ/μ1): 5 pg GCSF © was dissolved in 0.9% sodium hydride to a final volume of 250 μί. Mixture A : l〇x VEGF stock solution 36 μί

1〇χ GCSF stock solution 36 pL

0.9% sodium chloride 288 pL Mixture B (50 μΙ7 mice): 0.9% sodium chloride 360 pL Procedure The hair was obtained from an electric hair trimmer with 200927161 and depilatory cream. The lower back area of all animals was removed '俾 to expose approximately 2 to 3 cm 2 of skin. The mice were monitored for 1 day of animal testing to confirm that there was no skin irritation (skin irritati〇n). Photographs of the skin that was exposed on all animals were taken. After hair removal (days) and then on days i, 2, 7, 8, and 9, mice were injected subcutaneously with 50 nL of mixture A (treated) or mixture b (control group). The photos were taken on days 11, 12, 13 and 14. On day 14, the hair was removed and the length was measured. ® Results A summary of the results of the above study is presented in the table below. Hair sample 1 Hair sample 2 Hair sample 3 Hair sample 4 Hair sample 5 Control group # 1 ~~ϊ|·照组#2~ ——1_ 4 5 4 4 ' —4_ 4 Control group #3 3 3 3 4 4 Processed #1 7 6 6 7 /ς Processed #2 6 5 5 5 a Processed #3 6 6 6 6 5 Processed #4 7 7 6 6 6 Processed #5 5 6 6 5 5 The average control hair was 4.5 mm long. The average hair length in the treated cohort was 6 mm. Example 4 A slow release drug formulation was used for this study. The effect of growth factors (VEGF and GCSF) formulated in Carb〇Xymethyl cellul〇se (CMC) on the growth of mouse hair was observed. Materials and Methods Preparation of a 1 〇χ stock solution of VEGF (〇 2 μ§/μ1): 5〇 μ vegf 9 200927161 was dissolved in 0.9% sodium chloride to a final volume of 250 kL. Preparation of GCSF's l〇x stock solution (0.02 μ§/μ1): 5 pg of GCSF was dissolved in 0.9% sodium hydride to a final volume of 250 pL. Preparation of 2 C stock solution CMC (Stock CMC) (8% W/V): 0.4 g CMC was mixed in 5 mL of 0.9% sodium chloride.

Mixture A (50 pL/mouse): l〇x VEGF stock solution 36 μί l〇x GCSF stock solution 36 μί ❹ 2χ CMC 180 pL 0.9% sodium chloride 108 pL Mixture B (50 pL/mouse): 0.9% Gasified Sodium 180 pL 2χ CMC 180 pL Procedure Hair is removed from the underside of all animals using an electric hair trimmer and hair removal cream to expose approximately 2 to 3 cm2 of skin®. The mice were monitored for 1 day to confirm that there was no skin irritation. Photographs of the skin that was exposed on all animals were taken. After hair removal (Day 0) and then on Days 1, 2, 7, 8, and 9, mice were injected subcutaneously with 50 pL of Mix A or Mix B. Photographs were taken on days 11, 12, 13 and 14. On day 14, the hair was removed and the length was measured. Results 10 200927161

Note: The drug-treated group also confirmed the coarser hair shaft. By comparing the results of this example with the previous examples, it can be seen that: although VEGF and GCSF are administered in the absence of a few methylcelluloses, the rate of hair growth is lower. This means that the county methyl cellulose will delay the release of the active ingredient. As is known to those skilled in the art, other compounds and polymers can be added to and with GCSF, or in other combinations of drugs disclosed in this application, resulting in slow release of the drug. Example 5 During normal postnatal hair follicle development and during the use of chemotherapeutic drug [cyclophosphamide] depilation-induced adult hair cycling Angiogenesis (angi〇genesis) was first studied. C57BL/6 mice (Charles River) on day 0 (hair removal), day 09 (cyclohexylamine), days 10, 11, 12, 13 (treatment), followed by days 17, 18, 19 and 20 (Processing) was sacrificed. As shown in Figure 1, an increase of more than one-fold over the length of the hair during the 19-day 11 200927161 adult hair cycle was observed. Study design: 28 C57BL/6J, male, 7-week-old mice weighing 20 grams each were used for the study. Cyclophosphamide monohydrate (CYP, BioChemika, 28975-lg Sigma-Aldrich): CYP was dissolved in water to prepare a 10-fold solution of 150 mg/ml. VEGF (Human VEGF165): VEGF was dissolved in 0.9% sodium sulphate to a final concentration of 0.048 pg/pL. A 1 原 stock solution (0.48 gg/pL) was prepared. GCSF: GCSF was dissolved in 0.9% sodium hydride to a final concentration of p6 pg/pL. A 5x stock solution (0.3 pg/gL) was made. Mixture A (50 pL/mouse): 0.9% sodium sulphate mixture 50 (50 μί/mouse): l〇x VEGF stock solution 40 pL ¥ 0.9% sodium hydride 360 μΐ^ Mixture C (50 μΐ^/small) Rat): l〇x VEGF stock solution 40 μί 0.9% sodium 280 pL 5x GCSF 80 μί Mixture D (50 μ!^/mouse): 0.9% sodium hydride 320 μΐ^

5χ GCSF 80 pL 12 200927161 On the third day, the hair was removed from the lower back area of all animals using an electric hair trimmer and hair removal cream to expose approximately 2 to 3 cm2 of skin. The mice were monitored for 1 day to confirm that there was no skin irritation. Photographs of exposed skin on all animals were taken. On day 9, mice were injected subcutaneously with 100 pL of CYP. Mice were then injected subcutaneously with 50 μί of Mix A or Mix B at 10, 11, 12, 13, 17, 18, 19, 20, 24 and 31 days after depilation. It is noted that the injection site is moved 0.25 cm per day. The photographs were taken on days 8, 9, 12, and 13 and until 75% of the hair was regenerated. On the 31st day, the hair was removed and the length was measured. 〇 Results 20 hairs from each mouse were measured and hair was concentrated about each treatment. The average length is summarized in the following table: Group ABCDE treatment CYP + saline CYP + VEGF F CYP + GCSF no CYP hair length (mm) 3.5 5.4 7 6 7.5 The results of this study confirmed: cyclophosphamide (CYP) caused Severe hair loss and delayed hair growth. After 31 days, the animal hair showed an average length of 3.5 mm and was very short (CYP + saline). However, if the animal is treated with VEGF or GCSF after hair loss, or a combination of the two, the hair will grow rapidly. Animals treated with VEGF alone showed an average hair length of 5.4 mm (CYP + VEGF), and animals treated with GCSF showed an average hair length of 6 mm (CYP + GCSF). The best results were seen when the 13200927161 received both GCSF and VEGF. The average hair length is 7 mm (CYP+GCSF). Hair on animals that were not treated with CYP grew normally and reached an average hair length of 7.5 mm (no CYP). Summary, both VEGF and GCSF have the potential to rapidly restore cyclophosphamide-induced alopecia ° Example 6 Between hair growth observed during the growth phase (hair growth) The relationship between the enhancement and the increase in the thickness of the dermis and the subcutis is examined. It was found that the thickness of the interfollicular epidermis increased significantly from day 10 until reaching a maximum thickness on day 25 (Fig. 2). The temporal changes in hair follicles, the thickness of the dermis and the subcutaneous thickness, and the time of perifollicular vascularization are consistent with the temporal cohesion suggesting that the stimulation of hair growth is related to the generation of stem cells-induced jk tube (stem). The increase in cell-induced angiogenesis is associated with growth factors derived from the hair follicle itself or from the surrounding dermis and subcutaneous tissue keratinocytes. Example 7 One or more of GCSF, EGF, and VEGF levels will be encoded by a patient to encode GCSF, EGF or VEGF polypeptides, or functional fragments or analogs thereof (analog) At least one of the nucleotide sequences is increased. The level of GCSF, EGF, VEGF levels, or a combination thereof in a particular cell (such as 200927161, such as a keratinocyte) will be upregulated by a cell specific manner. Or is increased by introducing a transgene. Alternatively, the level of GCSF, EGF or VEGF levels, or a combination thereof, will be in a location-specific manner [the location is a scalp, hu (a scalp), a patient in need of treatment The beard), chest, or back is increased by increasing the expression in a position-specific manner, or by introducing a transgene. The mode of administration will be topical, systemic, oral, nasal, implant or injection dermally or subcutaneously. An surfactant or an agent that enhances the permeability on the skin will be used to aid in topical administration. Detergents [such as SDS, DMSO, bile salts, and fusidic acid derivatives] can be used for this purpose. Injections will be delivered as sterile formulations. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation will be vacuum drying and freeze-drying. The specific transduction of the protein in the target cell will be controlled by the specificity of the transfection provided by the gene delivery vehicle. Cell or tissue specificity will be controlled by regulatory sequences. Alternatively, genetically engineered cells 15 200927161 will be introduced. The cells may be of any cell type, but will preferably be fibroblasts, keratinocytes, epithelial cells, endothelial cells, glial cells or Precursors of these somatic cell types. The cells can be obtained from the same species or a donor of another species. The cells can be administered in the form of a gel or a biocompatible mesh. Example 8 One or more of the GCSF, EGF, and VEGF protein levels will be administered to a patient by GCSF, EGF, VEGF, combinations thereof, or one or more of their functional fragments or analogs. And it is increased. The mode of administration will be topical, systemic, oral, nasal, implantable or dermal or subcutaneous injection. The injectables will be delivered as a sterile formulation. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying. An surfactant or an agent that increases the permeability to the skin will be used to aid in topical administration. Detergents such as SDS, DMS0, bile salts, and fusidic acid derivatives can be used for this purpose. The proteins or a functional fragment or analog thereof may be delivered in the form of a gel, cream or liquid. In an illustrative example, an extract of Tridax procumbens will be used as a topical formula to increase the local concentration of VEGF and EGF. Example 9 One or more of the GCSF, EGF, and VEGF levels will be increased by administering a reagent or molecule to a disease 16 200927161 to increase the gene expression of GCSF, EGF, VEGF gene expression, or a combination thereof. . The molecule will be a stem cell stimulating factor, a FLT3 ligand, a cytokine or an interleukin-1. The mode of administration will be topical, systemic, oral, nasal, implantable or dermal or subcutaneous injection. The injectables will be delivered as a sterile formulation. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying. An surfactant or an agent that increases permeability on the skin will be used to aid in topical administration. Detergents such as SDS, DMS0, bile salts and fusidic acid derivatives can be used for this purpose. The agent or molecule can be delivered in the form of a gel, cream or liquid. The foregoing is an illustration of a specific example of the present technology. As is known to those skilled in the art, variations that do not change the scope of the technology are contemplated. For example, it is expected that growth factors (GCSF, VEGF, EGF) can be used alone or in combination of any two or three of GCSF, VEGF, EGF. A wide range of solvents for growth factors are contemplated which include a sterile saline solution. Any biodegradable polymer [which is biocompatible] can be used in conjunction with growth factors to cause slow release, such as, but not limited to, a protein [such as albumin (albumin), Gelatin or fibrinogen], a polysaccharide [such as dextran, starch, cellulose or carboxymethyl], poly (D, L lactic acid) Handing S)) [poly(D, L lactide)], poly 17 200927161 ❹

(glycolide), poly(caprolactone), a copolymer of lactic acid and glycolic acid, poly(d,l- Copolymer of poly(lactic acid) and copolymer of poly(lactic acid) and poly(caprolactone) [p〇ly(d, 1-lactide-co-glycolide)] Poly(caprolactone)]. GCSF, VEGF, EGF, and combinations thereof can be provided as a gene or gene that expresses GCSF, VEGF, EGF, and combinations thereof. Furthermore, a VEGF-stimulating factor can be additionally added to the formulation. In this regard, 'adenosine' or minoxidil is contemplated, but as is known to those skilled in the art, any VEGF-stimulating factor may be singly or in combination with other VEGFs. - a stimulus factor is added. BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 shows an amino acid sequence of GCSF according to a specific example of the present technology. Figure 2 shows the amino acid sequence of VEgf according to a specific example of the present technology. [Explanation of main component symbols] (None) 18 200927161 Sequence Listing <110> Parkson Biotech Co., Ltd. <120> Composition containing granule globule community stimulating factor (GCSF) for hair growth <130> Composition <;160> 2 <170> Patentln version 3.4 ❹ <210> 1 <211> 175 <212> PRT <213><220> Artificial <223>〇<400> Acid sequence 1

Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu 15 10 15

Lys Cys Leu Glu Gin Val Arg Lys lie Gin Gly Asp Gly Ala Ala Leu 20 25 30

Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 35 40 45 1 200927161

Val Leu Leu Gly His Ser Leu Gly lie Pro Trp Ala Pro Leu Ser Ser 50 55 60

Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80

Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly lie 85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala 100 105 1 10

Asp Phe Ala Thr Thr lie Trp Gin Gin Met Glu Glu Leu Gly Met Ala 115 120 125

Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala 130 135 140

Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 165 170 175 <210〉 2 <211〉 166

PRT <212> 200927161 <213> Artificial <220><223> VEGF amino acid sequence <400> 2

Met Ala Pro Met Ala Glu Gly Gly Gly Gin Asn His His Glu Val Val 15 10 15

Lys Phe Met Asp Val Tyr Gin Arg Ser Tyr Cys His Pro lie Glu Thr 20 25 30

Leu Val Asp lie Phe Gin Glu Tyr Pro Asp Glu lie Glu Tyr lie Phe 35 40 45

Lys Pro Ser Cys Val Pro Leu Met Arg Cys Gly Gly Cys Cys Asn Asp 50 55 60

Glu Gly Leu Glu Cys Val Pro Thr Glu Glu Ser Asn lie Thr Met Gin 〇 65 70 75 80 lie Met Arg lie Lys Pro His Gin Gly Gin His lie Gly Glu Met Ser 85 90 95

Phe Leu Gin His Asn Lys Cys Glu Cys Arg Pro Lys Lys Asp Arg Ala 100 105 110

Arg Gin Glu Asn Pro Cys Gly Pro Cys Ser Glu Arg Arg Lys His Leu 115 120 125 200927161

Phe Val Gin Asp Pro Gin Thr Cys Lys Cys Ser Cys Lys Asn Thr Asp 130 135 140

Ser Arg Cys Lys Ala Arg Gin Leu Glu Leu Asn Glu Arg Thr Cys Arg 145 150 155 160

Cys Asp Lys Pro Arg Arg 165

4

Claims (1)

200927161 VII. Scope of Application: 1. A pharmaceutical product containing a particle ball stimulating factor (GCSF) for the treatment of hair loss. 2. The use of claim 1 wherein the pharmaceutical further comprises vascular endothelial growth factor (VEGF). 3. The use of claim 1 or 2, wherein the pharmaceutical further comprises epidermal growth factor (EGF). 4. The use of claim 2, wherein the pharmaceutical product further comprises a biodegradable polymeric carrier. 5. The use according to claim 4, wherein the biodegradable polymerizable carrier is selected from the group consisting of: a protein, a polysaccharide, a gel, a poly(DL lactide), a poly( Glycolide), poly(caprolactone), a copolymer of lactic acid and glycolic acid 'poly(d,l-lactide-co-glycolide), and poly(lactic acid) and poly(self) a copolymer. 6. The use of claim 5, wherein the biodegradable polymeric carrier is one of albumin, gelatin, collagen or fibrinogen. 7. The use of claim 5, wherein the biodegradable polymeric carrier is one of polydextrose, starch, cellulose or carboxymethylcellulose. 8. The use of claim 7, wherein the biodegradable polymeric carrier is carboxymercaptocellulose. 9. The use of claim 2, wherein the pharmaceutical product is for topical application · 10. The use of claim 2, wherein the pharmaceutical product is for injection or planting 200927161. π. A particle ball community stimulating factor (GCSF) for use in the production of a medicament for the treatment of hair loss. 12. The use of claim 11, wherein the pharmaceutical further comprises vascular endothelial growth factor (VEGF). 13. The use of the scope of claim 2 wherein the pharmaceutical further comprises epidermal growth factor (EGF). 14. The use of the scope of claim 2, wherein the pharmaceutical further comprises a biodegradable polymeric carrier. 15. The use of claim 14, wherein the biodegradable polymeric carrier is selected from the group consisting of: a protein, a polysaccharide, a gel, a poly(D'L lactide), a poly (glycolide), poly(caprolactone), a copolymer of lactic acid and glycolic acid, poly(d,l-lactide-co-glycolide), and poly(lactic acid) and poly(caprolactone) a copolymer. W. The use of claim 15 wherein the biodegradable polymeric carrier is one of albumin, gelatin, collagen or fibrinogen, such as the use of claim 15 of the patent application, wherein The biodegradable polymeric carrier is one of polydextrose, starch, cellulose or carboxymethylcellulose. 18. The use according to claim 17, wherein the biodegradable polymeric carrier is carboxymethylcellulose. 19. The use of claim 15 wherein the biodegradable polymeric carrier is implantable. ϋ 200927161 2〇—A composition that promotes hair growth in one body, the composition comprising: a growth factor selected from the group consisting of: GCSF, VEGF, EGF, derivatives and analogs thereof, and a combination; and a solvent. 21. The composition of claim 2, wherein the solvent is a sterile liquid. 22. The composition of claim 21, wherein the sterile liquid is an aqueous salt solution. 23. The composition of any one of claims 2 to 22, wherein the growth factor comprises GCSF and VEGF. 24. The composition of claim 23, further comprising egf. 25. The composition of any one of claims 2 to 22, wherein the growth factor comprises GCSF and EGF. 26. The composition of claim 20, further comprising a biodegradable polymeric carrier. 27. The composition of claim 26, wherein the biodegradable polymeric carrier is selected from the group consisting of: a protein, a polysaccharide, a gel, a poly(D, L lactide), Poly(glycolide), poly(caprolactone), a copolymer of lactic acid and glycolic acid, poly(d,l-lactide-co-glycolide), and poly(lactic acid) and poly(within a copolymer of an ester). 28. The composition of claim 27, wherein the biodegradable polymeric carrier is one of albumin, gelatin, collagen or fibrinogen. 0 3 200927161 29. The composition of the item, wherein the biodegradable polymeric carrier is one of polydextrose, starch, cellulose or carboxymethylcellulose. 30. The composition of claim 29, wherein the biodegradable polymeric carrier is carboxymethylcellulose. 3 1. A composition for treating hair loss, the composition comprising: at least one nucleic acid encoding a growth factor selected from the group consisting of: GCSF, VEGF, EGF, derivatives and analogs thereof, and Combination; and a solvent. 32. The composition of claim 31, wherein the solvent is a sterile liquid. 33. The composition of claim 32, wherein the sterile liquid is an aqueous salt solution. The composition of any one of claims 31 to 33, wherein the nucleic acid encodes GCSF and VEGF. 35. The composition of claim 34, further comprising a nucleic acid encoding EGF. 36. The composition of claim 31, wherein the nucleic acid encodes a GCSF 〇 37. The composition of claim 31, further comprising a biodegradable polymeric carrier. 38. The composition of claim 37, wherein the biodegradable polymeric carrier is selected from the group consisting of: a protein, a polysaccharide, a gel, a poly 4 200927161 (d, l lactide) ), poly(glycolide), poly(caprolactone), a copolymer of lactic acid and glycolic acid, poly(d,l-lactide-co-glycolide), and poly(lactic acid) and poly( a copolymer of caprolactone). 39. The composition of claim 20, further comprising a VEGF-stimulating factor. 40. A transfected cell for use in the treatment of alopecia, the cell being transformed with at least one isolated nucleic acid encoding a growth factor selected from the group consisting of: GCSF, VEGF, EGF, derivatives and analogs thereof And their combinations. ❹ 41. The transformed cell of claim 40, wherein the nucleic acid encodes GCSF and VEGF. 42. The transfected cell of claim 41, further comprising a nucleic acid encoding EGF. 43. The transformed cell of claim 4, wherein the nucleic acid encodes GCSF and EGF. 44. A method for promoting hair growth in a body, comprising: ◎ preparing a pharmaceutical product comprising a particle ball stimulating factor (GCsf); and administering the drug to the individual to promote hair Growing. 45. The method of claim 44, wherein the pharmaceutical further comprises vascular endothelial growth factor (VEGF). 46. The method of claim 44, wherein the pharmaceutical further comprises epidermal growth factor (EGF). 47. The method of claim 45, wherein the pharmaceutical product further comprises a biodegradable polymeric carrier. 48. The method of claim 47, wherein the biodegradable polymer 5 200927161 sex agent is selected from the group consisting of: protein, a polysaccharide, a gel, poly (D, L lactide) , poly(glycolide), poly(caprolactone), a copolymer of lactic acid and glycolic acid, poly(d,1-lactide-co-glycolide), and poly(lactic acid) and poly(hexyl) a copolymer of lactones. 49. The method of claim 48, wherein the biodegradable polymeric carrier is one of albumin, gelatin, collagen or fibrinogen. 50. The method of claim 48 Wherein the biodegradable polymeric carrier is one of polydextrose, starch, cellulose or carboxy-mercaptocellulose. 51. The method of claim 5, wherein the biodegradable polymeric carrier is carboxymercaptocellulose. 52. The method of claim 45, wherein the pharmaceutical further comprises a VEGF-stimulating factor in a salt. 53. The method of claim 52, wherein the VEGF-stimulating factor is minoxidil or adenosine. 6